Ketoanalogues & essential amino acids

Indications
Prevention and therapy of damages due to faulty or deficient protein met
abolism in chronic renal insufficiency in connection with limited protein in foo
d of 40 g/day (for adults) and less; ie, generally in patients with a glomerular
filtration rate (GFR) between 5 and about 15 mL/min.
Dosage
For oral use. Adults 70 kg body weight: Take 4-8 tabs 3 times a day duri
ng meals if not otherwise prescribed. Swallow whole.
Duration of Treatment: Ketosteril tablets are given as long as the glomerular fi
ltration rate is between 5 and about 15 mL/min. Simultaneously, food should cont
ain 40 g/day protein or less in adults.
Administration
Should be taken with food (Swallow whole, do not chew/crush.).
Contraindications
Hypercalcemia, disturbed amino acid metabolism.
Special Precautions
Use in pregnancy: No experience has been made so far with the applicatio
n in pregnancy.
Use in children: No experience has been made so far with the application in pedi
atrics.
Side Effects
Hypercalcemia. Monitor regularly the serum calcium level. Ensure the suf
ficient supply with calories.
Drug Interactions
The simultaneous administration of medications containing calcium (eg, a
cetolyte) may lead to pathological increases of the serum calcium level or inten
sification. As the uremia symptoms improve with Ketosteril, a possible administr
ation of aluminium hydroxide should be reduced. Pay attention to a reduction of
serum phosphate. In order not to interfere with absorption, do not take drugs to
gether with Ketosteril that form sparingly soluble compounds with calcium (eg, t
etracyclines).
View more drug interactions for Ketosteril
Storage
Store at temperatures not exceeding 30°C.
Description
Each tablet contains calcium-3-methyl-2-oxo-valerate (α-keto n logue to is
oleucine, c lcium s lt) 67 mg, c lcium-4-methyl-2-oxo-v ler te (α-keto n logue to
leucine, c lcium s lt) 101 mg, c lcium-2-oxo-3-phenyl-propion te (α-keto n logue t
o phenyl l nine, c lcium s lt) 68 mg, c lcium-3-methyl-2-oxo-butyr te (α-keto n lo
gue to v line, c lcium s lt) 86 mg, c lcium-dl-2-hydroxy-4-(methylthio)butyr te
(α-hydroxy n logue of methionine, c lcium s lt) 59 mg, L-lysine cet te (equiv len
t to L-lysine 75 mg) 105 mg, L-threonine 53 mg, L-tryptoph n 23 mg, L-histidine
38 mg nd L-tyrosine 30 mg. The tot l nitrogen/t blet content is 36 mg nd the c
lcium/t blet content is 1.25 mmol which is equiv lent to 0.05 g.
MIMS Cl ss
Other Drugs Acting on the Genito-Urin ry System
ATC Cl ssific tion
G04BX - Other urologic ls ;
her peutic Actions:
Norm lizes met bolic process, promotes recycling product exch nge. REduces ion c
oncentr tion of pot ssium, m gnesium nd phosph te.
Indic tions
* Protein energy m lnutrition
* Prevention nd tre tment of conditions c used by modified or insufficient
protein met bolism in chronic ren l f ilure
Contr indic tions:
* Allergy nd hypersensitivity to ny content of this drug
* Hyperc lcemi
* Disturbed mino cid met bolism
* C ution use for p tietn with phenylketonuri
Dos ge
* Four to eight t bs TID
* 1 t b/5kg body weight/d y
Adverse
* Hyperc lcemi m y develop
Nursing Consider tions
* Ev lu te for ny contr indic tions
* T ke drug s prescribed
* W rn the p tient bout possible side effects nd how to recognize them
* Give with food if GI upset occurs
* Frequently ssess for hyperc lcemi